Cite
HARVARD Citation
Biester, T. et al. (2021). Add‐on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. Diabetes, obesity & metabolism. 23 (2), pp. 599-608. [Online].